文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

高剂量预防性抗凝对重症COVID-19肺炎危重患者的影响

Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia.
PubMed 文献 · Chest · 2021-01-16
一句话结论在重症COVID-19肺炎危重患者中,高剂量预防性抗凝与血栓并发症风险降低相关(HR 0.81),且不增加出血风险。

这项法国8个ICU的观察性研究纳入538例连续收治的COVID-19危重患者,从ICU入住至第14天收集数据。采用时间变化暴露模型和逆概率治疗加权评估高剂量预防性抗凝(中间剂量或等效治疗剂量)的效果。结果显示血栓并发症发生率为22.7%(95%CI 19.2%-26.3%),肺栓塞占52%;高剂量预防性抗凝与血栓并发症风险显著降低相关(HR 0.81;95%CI 0.66-0.99),且不增加出血风险(HR 1.11;95%CI 0.70-1.75)。作者认为需要随机对照试验比较预防性与更高剂量抗凝以确认这些结果。

要点

  • 在538例重症COVID-19肺炎危重患者中,血栓并发症发生率为22.7%(95%CI 19.2%-26.3%),其中肺栓塞占52%。
  • 高剂量预防性抗凝(中间剂量或等效治疗剂量)与血栓并发症风险显著降低相关(HR 0.81;95%CI 0.66-0.99)。
  • 高剂量预防性抗凝未增加出血风险(HR 1.11;95%CI 0.70-1.75)。
  • 该研究为观察性设计,采用时间变化暴露模型和逆概率治疗加权,结果需随机对照试验确认。

适用人群与场景

  • 法国8个ICU连续收治的COVID-19危重患者,从ICU入住至第14天收集数据。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:观察性研究,纳入538例连续患者,来自8个法国ICU。
  • 主要终点:血栓并发症发生率为22.7%(95%CI 19.2%-26.3%),肺栓塞占52%。
  • 高剂量预防性抗凝(中间剂量或等效治疗剂量)与血栓并发症风险降低相关(HR 0.81;95%CI 0.66-0.99)。
  • 出血风险:高剂量预防性抗凝未增加出血风险(HR 1.11;95%CI 0.70-1.75)。

证据类型、等级与局限

  • 证据类型:观察性研究(单国多中心,8个ICU),采用时间变化暴露模型和逆概率治疗加权。
  • 局限:观察性设计,可能存在残余混杂;需要随机对照试验确认。

对床旁实践的改变

  • 对于重症COVID-19肺炎危重患者,高剂量预防性抗凝可能降低血栓并发症风险且不增加出血,但证据来自观察性研究,需随机对照试验确认后方可改变常规实践。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Because of the high risk of thrombotic complications (TCs) during SARS-CoV-2 infection, several scientific societies have proposed to increase the dose of preventive anticoagulation, although arguments in favor of this strategy are inconsistent.

RESEARCH QUESTION: What is the incidence of TC in critically ill patients with COVID-19 and what is the relationship between the dose of anticoagulant therapy and the incidence of TC?

STUDY DESIGN AND METHODS: All consecutive patients referred to eight French ICUs for COVID-19 were included in this observational study. Clinical and laboratory data were collected from ICU admission to day 14, including anticoagulation status and thrombotic and hemorrhagic events. The effect of high-dose prophylactic anticoagulation (either at intermediate or equivalent to therapeutic dose), defined using a standardized protocol of classification, was assessed using a time-varying exposure model using inverse probability of treatment weight.

RESULTS: Of 538 patients included, 104 patients experienced a total of 122 TCs with an incidence of 22.7% (95% CI, 19.2%-26.3%). Pulmonary embolism accounted for 52% of the recorded TCs. High-dose prophylactic anticoagulation was associated with a significant reduced risk of TC (hazard ratio, 0.81; 95% CI, 0.66-0.99) without increasing the risk of bleeding (HR, 1.11; 95% CI, 0.70-1.75).

INTERPRETATION: High-dose prophylactic anticoagulation is associated with a reduction in thrombotic complications in critically ill patients with COVID-19 without an increased risk of hemorrhage. Randomized controlled trials comparing prophylaxis with higher doses of anticoagulants are needed to confirm these results.

TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT04405869; URL: www.clinicaltrials.gov.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Tacquard C, Mansour A, Godon A, et al. Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia. Chest. 2021. PMID: 33465342. doi:10.1016/j.chest.2021.01.017

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。